Information regarding the public offer from ANI Pharmaceuticals

On 5 November 2026, ANI Pharmaceuticals, Inc. (“ANI”) announced a recommended public offer to the shareholders of Egetis Therapeutics AB (publ) (“Egetis”) and the holder of the convertible loan 2023:1 (the “Convertible”) and the warrants 2023/2033:1 (the “Warrants”) issued by Egetis, to tender all shares, the Convertible and the Warrants to ANI at a price of SEK 11.25 in cash per share, SEK 65,750,817 in cash for the EUR 3 million principal amount of the Convertible and SEK 6.99 in cash per Warrant (the “Offer”).

The Board of Directors of Egetis has unanimously decided to recommend the shareholders of Egetis and the holder of the Convertible and the Warrants to accept the Offer.

For more information, please refer to ANI’s website relating to the Offer, www.biopharma-offer.com.

Press releases

Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals